Soligenix, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need. The Company operates in two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics business segment intends to develop oral beclomethasone dipropionate (oral BDP) indications such as pediatric Crohn�s disease and acute radiation enteritis. Its Vaccines/BioDefense business segment includes active development programs for RiVaxTM, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome (GI ARS) therapeutic. In December 2012, it acquired a drug technology, it refers to as SGX94, representing an approach to modulation of the innate immune system. SGX94 is an IDR that regulates the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing.